Sickle cell disease trials in Belgium

In Belgium 11 Also abroad 204

11 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
Where
Brussels, Edegem
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07224360 · EU 2025-521154-42-00
Phase 4Enrolling by invitation
A Study to Provide Access to Mitapivat for Participants Who Previously Participated in an Agios-Sponsored Mitapivat Study
Where
Anderlecht
Age
18 years and over
People
55 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT05777993 · EU 2026-526243-35-00
Phase 3Taking people
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Where
Anderlecht, Antwerp, Liège
Age
12 years and over
People
159 worldwide
Run by
Agios Pharmaceuticals, Inc.
See details and how to joinNCT07656415 · EU 2026-526778-18-00
Phase 3Taking people
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Where
Brussels, Leuven, Liège
Age
10 years to 65 years
People
192 worldwide
Run by
Sanofi
See details and how to joinNCT06975865
Phase 2Taking people
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
Where
Anderlecht, Edegem, Leuven, Liège
Age
12 years and over
People
70 worldwide
Run by
CSL Behring
See details and how to joinNCT06699849 · EU 2024-513440-29-00
Phase 3Taking people
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Where
Anderlecht, Brussels, Edegem, Leuven
Age
12 years and over
People
510 worldwide
Run by
Novo Nordisk A/S
See details and how to joinNCT06612268 · EU 2023-509175-16-00
Phase 2/3Taking people
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
Where
Brussels, Sint-Lambrechts-Woluwe
Age
12 years to 64 years
People
389 worldwide
Run by
Pfizer
See details and how to joinNCT05431088 · EU 2023-508766-14-00
Phase 3Enrolling by invitation
A Long-term Follow-up Study in Participants Who Received CTX001
Where
Brussels
Age
2 years to 64 years
People
160 worldwide
Run by
Vertex Pharmaceuticals Incorporated
See details and how to joinNCT04208529 · EU 2024-512654-19-00
Phase 4Taking people
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Where
Brussels, Liège
Age
6 months to 100 years
People
130 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04657822 · EU 2024-510734-41-00
Phase 4Taking people
Morphine PCA vs Morphine and Lidocaine PCA for the treatment of vaso-occlusive crisis-related pain in sickle-cell anaemia patients: a prospective, randomized, double blind monocentric trial.
Where
Brussels
Age
18 years and over
People
40
Run by
CHU Saint Pierre
See details and how to join2025-523777-41-01 · EU 2025-523777-41-01
No phaseTaking people
Study of the Role of Genetic Modifiers in Hemoglobinopathies
Where
Leuven
Age
2 years and over
People
30,000 worldwide
Run by
Cyprus Institute of Neurology and Genetics
See details and how to joinNCT05799118